As autophagy seems to play an important role in this aggressive blood cancer, it would be interesting to test/develop therapeutics to target this process, for instance nano-targeting and/or modulation of key autophagy and apoptosis components (such as beclin-1 and Bcl-2) in M1 macrophages. The gene discussed is BCL2; the disease is hematopoietic and lymphoid system neoplasm.